Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Parker-Hannifin trades at $953.44 heading into its October 28 results, and the stock's 3.2% drop on the week has narrowed the already-notable gap to analyst targets only slightly, leaving the Street's conviction and the market's pricing firmly at odds.
The freshest move on the Street this week comes from TD Cowen, which raised its target to $950 from $850 on October 14 while keeping a Hold rating. That puts the new target virtually at the current price, making it the least optimistic reading among recent coverage. Citigroup also lifted marginally, nudging from $1,232 to $1,234 on October 12 with a maintained Buy. JP Morgan trimmed to $1,131 from $1,140 last week, though it held Overweight. Taken together, the tone remains constructive on balance, with the majority of analysts clustered well above $1,100, but TD Cowen's Hold and Wells Fargo's Equal-Weight initiation at $1,050 in late September represent the cautious fringe. The mean target is $1,159, implying roughly 22% upside from here. On valuation, the trailing P/E is 24.6x and EV/EBITDA is 17.6x, with both multiples easing over the past week as the stock has slipped. Earnings momentum is solid, with forward EPS growth ranking in the 81st percentile of the universe, though value scores remain subdued with EV/EBIT ranking just 24th percentile.
The positioning picture remains firmly unexciting for a stock this close to earnings. Short interest is just 1.1% of the free float, and while it has crept up 15% over the past month in share terms, the absolute level stays trivial. Borrow availability is effectively unlimited, well above any level that would suggest meaningful squeeze potential or difficulty sourcing shares. Cost to borrow has also eased, falling 40% on the week to 0.27%, near the lowest reading of the past six weeks. The ORTEX short score is 29.8, placing PH in the 74th percentile for low short pressure. Options positioning is almost exactly neutral: the put/call ratio is 0.83, barely a whisker below its 20-day average of 0.83, and well within normal range. The 52-week high on the PCR is 1.28, so there is no sign of defensive hedging building ahead of the print.
The most interesting piece of alt data this week is attention-related rather than financial. Wikipedia page views for PH are running at a z-score of 1.6 against the company's own 90-day history, a modest but visible uptick in retail interest. This is an attention signal, not a revenue indicator, and there are no measured leading datasets for PH from the alt data layer that bear on the forthcoming print.
On the ownership front, the register is orderly. BlackRock holds 8.2% and recently added 390,000 shares. State Street and Vanguard Capital Management both hold just above 7%. Insider activity over the past 90 days has tilted modestly negative on an open-market basis: the EVP of HR sold $2.6m in August, the head of the Fluid Connections Group sold around $1.3m, and a director disposed of a small stake in September. None were under a 10b5-1 plan. The net 90-day insider position is minus $18.6m across transactions of various types. After the August print, which pushed the stock up 7.7% in a single day and 6.2% over the following five days, insiders used the elevated price level to trim modestly. That pattern reads as normal housekeeping rather than a directional call.
Close peers moved in a similar direction on the week. DCI fell 3.3%, WTS fell 3.1%, and SXI dropped 4.9%, suggesting the modest weakness in PH reflects sector rotation pressure rather than a stock-specific concern. What to watch in the two weeks to October 28 is whether the stock can narrow the gap to Street targets, or whether the absence of short-side pressure and options defensiveness means the market is simply waiting for the results before forming a clearer view.
See the live data behind this article on ORTEX.
Open PH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
